• 22 February 2018

    Takeda and Wave Life Sciences to develop neurological treatments

    Takeda Pharmaceutical has signed a research, development and commercial collaboration and multi-programme option agreement with Wave Life Sciences to create new antisense oligonucleotides as treatments for genetically defined neurological diseases.

  • 21 February 2018

    AbbVie and Voyager target one-time treatment for Alzheimer’s

    AbbVie has signed an exclusive strategic collaboration and option agreement with gene therapy firm Voyager Therapeutics for the development and commercialisation of new treatments for neurodegenerative diseases, including Alzheimer’s disease.